Dr Han Hsi Wong

Cambridge University Hospitals NHS Foundation Trust

University departments
Department of Oncology

Position: Consultant Medical Oncologist
Personal home page: http://www.researchgate.net/profile/han_wong

PubMed journal articles - click here

Research description

Treatment of bone and soft-tissue sarcomas and testicular (germ cell) cancer.

Research Programme
Paediatric Cancer
Tumour type interests
Bone and connective tissue

Key publications

1. Doherty GJ, Davidson D, Wong HH, Hatcher HM. Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma. Anticancer Drugs. 2019;30(1):110-5.
2. Weaver HL, Preston SD, Wong HH, et al. Surgical resection of a massive primary mediastinal liposarcoma with cervical extension. Ann R Coll Surg Engl. 2018;100(2):e22-e27.
3. Boulos S, Mazhar D, Warren AY, Wong HH. Adjuvant chemotherapy and follow-up for recurrences in localized testicular cancer. Future Oncol. 2017;13(11):947-50.
4. Szucs Z, Messiou C, Wong HH, et al. Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs. 2017;28(4):421-426.
5. Wong HH, Barton C, Acton G, et al. Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: the Cancer Research UK experience. Eur J Cancer. 2016;66:9-16.
6. Szucs Z, Davidson D, Wong HH, et al. A comprehensive single institutional review of 2 years in a designated fast-track sarcoma diagnostic clinic linked with a Sarcoma Specialist Advisory Group: meeting the target but failing the task? Sarcoma. 2016;2016:6032606.
7. Wong HH, Halford S. Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? Lancet Oncol. 2015;16(13):1287-8.
8. Ghorani E, Wong HH, Hewitt C, et al. Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience. Oncology. 2015;89(5):281-7.
9. Wong HH, Gounaris I, McCormack A, et al. Presentation and management of pulmonary artery sarcoma. Clin Sarcoma Res. 2015;5(1):3.
10. Wong HH, Collins J, McAdam K, Wilson C. Trastuzumab beyond progression in advanced breast cancer: national guidance versus oncologist’s decision. Oncology. 2014;86(1):22-3.
11. Wong HH, Hatcher HM, Benson C, et al. Desmoplastic small round cell tumours: characteristics and prognostic factors of 41 patients and review of the literature. Clin Sarcoma Res. 2013;3(1):14.
12. Wong HH, Siegler C, Grainger S, et al. Improving clinical trial recruitment: experience of a tertiary renal oncology centre. Oncology. 2013;85(5):297-8.
13. Wong HH, Eisen T. Tivozanib for the treatment of metastatic renal cancer. Expert Rev Anticancer Ther. 2013;13(6):649-60.
14. Wong HH, Parkinson C, Ledermann JA, et al. Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation. Gynecol Oncol Case Rep. 2012;3:7-10.
15. Wong HH, Jiang G, Gangeswaran R, et al. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11. Mol Ther. 2012;20(2):306-16.
16. Jiang G, Cao F, Ren G, et al. PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut. 2010;59(11):1535-44.
17. Wong HH, Lemoine NR. Novel therapies for pancreatic cancer: setbacks and progress. Future Oncol. 2010;6(7):1061-4.
18. Wong HH, Lemoine NR, Wang Y. Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses. 2010;2(1):78-106.
19. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol. 2009;6(7):412-22.
20. Danovi SA, Wong HH, Lemoine NR. Targeted therapies for pancreatic cancer. Br Med Bull. 2008;87:97-130.
21. Wong HH, Lemoine NR. Biological approaches to therapy of pancreatic cancer. Pancreatology. 2008;8(4-5):431-61.

Book chapters:
1. Wong HH, Greef B, Eisen T. Treatment of metastatic renal cancer. In: Hamdy F, Eardley I, editors. Oxford textbook of urological surgery. Oxford: Oxford University Press; 2017. p 757-75.
2. Ghorani E, Wong HH, Buscombe J, et al. Current management of gastroenteropancreatic neuroendocrine tumours. In: Shrikhande SV, Sirohi B, editors. Modern gastrointestinal oncology. India: Elsevier; 2015. p. 424-443.
3. Wong HH, Eisen T. First-generation tyrosine kinase inhibitors: clinical results. In: Bukowski RM, Figlin RA, Motzer R, editors. Renal cell carcinoma: molecular targets and clinical application. 3rd ed. New York: Springer; 2015. p. 177-205.
4. Hallden G, Wang Y, Wong HH, Lemoine NR. Oncolytic adenoviruses for cancer gene therapy. In: Scherman D, editor. Advanced textbook on gene transfer, gene therapy and genetic pharmacology: principles, delivery and pharmacological and biomedical applications of nucleotide-based therapies. London: Imperial College Press; 2014. p. 307-329.
5. Wong HH, Lemoine NR. Gene therapy for pancreatic cancer. In: Neoptolemos JP, Urrutia R, Abbruzzese JL, Büchler MW, editors. Pancreatic cancer. New York: Springer; 2010. p. 1237-68.